These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22640784)

  • 1. [Patients with psoriasis have an increased risk of cardiovascular diseases].
    Ahlehoff O; Gislason G; Lindhardsen J; Skov L; Hansen PR
    Ugeskr Laeger; 2012 May; 174(21):1450-2. PubMed ID: 22640784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis: an opportunity to identify cardiovascular risk.
    Federman DG; Shelling M; Prodanovich S; Gunderson CG; Kirsner RS
    Br J Dermatol; 2009 Jan; 160(1):1-7. PubMed ID: 19016698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Psoriasis and atherothrombotic disease].
    Ahlehoff O; Gislason GH; Skov L; Hansen PR
    Ugeskr Laeger; 2010 Jun; 172(26):1983-6. PubMed ID: 20654288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psoriasis: a skin disease associated with increased cardiovascular risk.
    González-Gay MA; González-Vela C; González-Juanatey C
    Actas Dermosifiliogr; 2012 Sep; 103(7):595-8. PubMed ID: 22465257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comorbidities in patients with psoriasis.
    Gottlieb AB; Dann F
    Am J Med; 2009 Dec; 122(12):1150.e1-9. PubMed ID: 19958894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.
    Ahlehoff O; Skov L; Gislason G; Lindhardsen J; Kristensen SL; Iversen L; Lasthein S; Gniadecki R; Dam TN; Torp-Pedersen C; Hansen PR
    J Intern Med; 2013 Feb; 273(2):197-204. PubMed ID: 22963528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis and cardiovascular disorders.
    Ryan C; Menter A
    G Ital Dermatol Venereol; 2012 Apr; 147(2):179-87. PubMed ID: 22481581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
    Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
    Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate and other chemotherapeutic agents used to treat psoriasis.
    Jeffes EW; Weinstein GD
    Dermatol Clin; 1995 Oct; 13(4):875-90. PubMed ID: 8785891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights on methotrexate in psoriatic disease.
    Greb JE; Goldminz AM; Gottlieb AB
    Clin Immunol; 2016 Nov; 172():61-64. PubMed ID: 27455859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Excess mortality from cardiovascular disease in patients with rheumatoid arthritis].
    Lindhardsen J; Gislason GH; Ahlehoff O; Madsen OR; Hansen PR
    Ugeskr Laeger; 2011 Jan; 173(5):343-6. PubMed ID: 21276397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis.
    Kaye JA; Li L; Jick SS
    Br J Dermatol; 2008 Sep; 159(4):895-902. PubMed ID: 18616778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Update on current care guidelines: psoriasis and psoriatic arthritis].
    Duodecim; 2012; 128(15):1620-1. PubMed ID: 22970613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methotrexate treatment in non-cancerous disorders].
    Cogan E
    Rev Med Brux; 1995; 16(4):300-3. PubMed ID: 7481247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences.
    Boehncke WH; Boehncke S
    G Ital Dermatol Venereol; 2008 Oct; 143(5):307-13. PubMed ID: 18833072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superimposed linear psoriasis: low effectiveness of biologic therapy.
    Colombo L; Marconi M; Mapelli ET; Crespi E; Gualandri L; Menni S; Cerri A
    G Ital Dermatol Venereol; 2011 Aug; 146(4):311-3. PubMed ID: 21785401
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular risk and psoriasis: beyond the traditional risk factors.
    Coumbe AG; Pritzker MR; Duprez DA
    Am J Med; 2014 Jan; 127(1):12-8. PubMed ID: 24161194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The concept of psoriasis as a systemic inflammation: implications for disease management.
    Reich K
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():3-11. PubMed ID: 22356630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy.
    Su YS; Yu HS; Li WC; Ko YC; Chen GS; Wu CS; Lu YW; Yang YH; Lan CC
    J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):876-83. PubMed ID: 22702656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
    Prodanovich S; Ma F; Taylor JR; Pezon C; Fasihi T; Kirsner RS
    J Am Acad Dermatol; 2005 Feb; 52(2):262-7. PubMed ID: 15692471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.